HRPC(SH:600829) Shang Hai Zheng Quan Bao·2025-11-11 19:27Core Viewpoint - The stock of Harbin Pharmaceutical Group People's Tongtai Pharmaceutical Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days [2][4]. Group 1: Abnormal Trading Fluctuation - The company's stock price increased significantly on November 7, 10, and 11, 2025, leading to a cumulative price deviation of over 20%, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange regulations [2][4]. - The company conducted a self-examination and confirmed that its business operations are normal, with no undisclosed significant information affecting the stock price [5]. Group 2: Verification with Major Shareholders - The company consulted its controlling shareholder, Harbin Pharmaceutical Group Co., Ltd., and confirmed that there are no undisclosed significant matters that could influence the stock price, such as major asset restructuring or significant transactions [5]. - No major events that could significantly impact the stock price were identified, and there were no media reports or market rumors requiring clarification [5]. Group 3: Board of Directors' Statement - The Board of Directors confirmed that there are no undisclosed matters or plans that could affect the stock price, and previous disclosures do not require correction or supplementation [7].